跳至主要内容
临床试验/NCT01390038
NCT01390038已完成3 期

Simpliciti IDE Trial

Stryker Trauma and Extremities28 个研究点 分布在 1 个国家目标入组 157 人开始时间: 2011年7月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
157
试验地点
28
主要终点
Device Success Rate

研究概览

简要总结

The purpose of this study is to demonstrate safety and efficacy of the Simpliciti Shoulder System in total shoulder arthroplasty.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult subject 22 years or older
  • Clinical indication for total shoulder replacement due to primary diagnosis of arthritis. Primary arthritis for this study includes osteoarthritis, and/or traumatic arthritis.
  • Scapula and proximal humerus must have reached skeletal maturity
  • Subject with a Constant Score ≥ 20
  • Willing and able to comply with the protocol
  • Willing and able to sign the informed consent (or the Legally Authorized Representative will sign for the subject)

排除标准

  • Lack of sufficient sound bone to seat and support the implant such as:
  • Rapid joint destruction, marked bone loss or bone resorption;
  • Destruction of the proximal humerus that precludes rigid fixation of the humeral component; and
  • Osteomalacia
  • Metal allergies or sensitivity, including a known allergic reaction to implant metals (e.g., nickel) or polyethylene
  • Infection at or near the site of implantation, including:
  • Glenohumeral joint infection
  • Osteomyelitis
  • Distant or systemic infection
  • Medical conditions or balance impairments that could lead to falls
  • Prior open shoulder surgery on the shoulder to be treated in the study including failed rotator cuff surgery, but excluding successful shoulder arthroscopy
  • Any full thickness rotator cuff tear at the time of surgery or a nonfunctional rotator cuff
  • Excessive glenoid bone loss defined by preoperative computed tomography (CT) scans of the shoulder which show insufficient glenoid bone, or insufficient bone identified at the time of surgery
  • Metabolic disorders which may impair bone function
  • Nonfunctional deltoid muscle
  • Neuromuscular compromise condition of the shoulder (e.g., neuropathic joints or brachioplexus injury with a flail shoulder joint)
  • Known active metastatic or neoplastic diseases, Paget's disease or Charcot's disease
  • Currently, or within the last 6 months, or planning to be on chemotherapy or radiation
  • Currently taking > 5mg/day corticosteroids (e.g. prednisone) excluding inhalers, within 3 months prior to surgery
  • Female subjects who are pregnant or planning to become pregnant within the study period
  • In the surgeon's opinion, the subject is unable to understand the study or be compliant with the follow up or have a history of non-compliance with medical advice
  • History of any cognitive or mental health status that would interfere with study participation
  • Alcohol or drug abuse
  • Engages in manual labor or sports activities that could affect shoulder outcome
  • Currently enrolled in any clinical research study that might interfere with the current study endpoints

结局指标

主要结局

Device Success Rate

时间窗: 24 months

A subject is a Patient Success at 24-months if: 1. There is NO continuous radiolucent line around the prosthesis; and 2. The adjusted Constant Score is \> 85 (successful outcome); and 3. They did not have revision surgery; and 4. They did not have a system-related serious adverse event.

次要结局

  • Quality of Life(24 months)
  • Range of Motion(24 months)
  • Strength(24 months)
  • Pain: Visual Analog Scale(24 Months)
  • Device Parameters(24 months)
  • American Shoulder and Elbow Surgeon Score(24 Months)

研究者

发起方
Stryker Trauma and Extremities
申办方类型
Industry
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验